BGP Stent as Bridging Stent in FEVAR

Physician-Initiated Trial Investigating the BeGraft Peripheral Stent Graft System as Bridging Stent in FEVAR for Complex Aortic Aneurysms

The objective of this clinical investigation is to evaluate, in a controlled setting, the safety and performance of the BeGraft Peripheral (BGP) balloon expandable covered stent Graft System (Bentley InnoMed, Hechingen, Germany) implanted as bridging stent in FEVAR (fenestrated endovascular aortic repair) for complex aortic aneurysms.

Study Overview

• Status: Active, not recruiting
• Conditions: Thoracoabdominal Aortic Aneurysm, Without Mention of Rupture; Abdominal Aortic Aneurysm, Without Mention of Rupture
• Intervention / Treatment: Device: BeGraft Peripheral (BGP) Stent Graft System as bridging stent

• Study Type: Interventional
• Enrollment (Actual): 103
• Phase: Phase 3

Contacts and Locations

Study Locations

• Germany
  • Aachen, Germany
    • Alexander Gombert
  • Freiburg, Germany, 79106
    • University Heart Center Freiburg- Bad Krozingen
  • Gießen, Germany
    • University Hospital Gießen
  • Hamburg, Germany, 20246
    • University Hospital Hamburg-Eppendorf
  • München, Germany
    • University Hospital LMU Munich
  • Münster, Germany, 48145
    • Martin Austermann
  • Nürnberg, Germany
    • Klinikum Nürnberg Süd
  • Regensburg, Germany
    • University Hospital Regensburg
  • Stuttgart, Germany
    • Hospital Stuttgart

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 53 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patient eligible for elective repair of AAA/TAAA extent IV with FEVAR in accordance with the applicable guidelines for vascular interventions (Aneurysm size 5.5cm or aneurysm growth of >5 mm within 6 months or 1 cm within 1 year).
• Patient is willing to comply with specified follow-up evaluations at the specified times
• Patient is >55 years old
• Patient understands the nature of the procedure and provides written informed consent, prior to enrollment in the study
• Patient has a projected life-expectancy of at least 12-months
• Indication of elective repair of AAA or TAAA with FEVAR in accordance with the applicable guidelines for vascular interventions
• Patient needs to have a landing zone in their target vessel of at least 10mm
• No early important division branch from the target vessel with risk of coverage
• Absence of dissection
• Target vessels (renal arteries, superior mesenteric artery and celiac trunk) should have a diameter between 5 and 10 mm
• Patient eligible for fenestrated endovascular repair as per IFU of the fenestrated endograft
• Angulation of the aorta at the level of the target vessels <45 degrees
• The fenestrated endograft has to be constructed so the fenestrations lie in front of the orifice of the target vessel, and the gap between the fenestration and the orifice of the target vessel should not exceed 10mm.

Exclusion Criteria:

• Previously implanted endograft
• Patients refusing treatment
• Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated
• Patients with uncorrected bleeding disorders or heparin induced thrombozytopenia
• Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding
• Any planned surgical intervention/procedure within 30 days of the study procedure
• Any patient considered to be hemodynamically unstable at onset of procedure
• Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period.
• Patients with diffuse distal disease resulting in poor stent outflow
• Fresh thrombus formation
• Stenosed (>50%) or occluded target vessel
• Angulation between renal artery and aortic wall <30 degrees
• Patients with known hypersensitivity to the stent material (L605) and/or PTFE
• Hybrid Approach
• Patients with a connective tissue disorder
• Patients with mycotic or inflammatory aneurysm
• Myocardial infarction or stroke within 3 months prior to the procedure
• Patients with an unstable angina pectoris or heart insufficiency NYHA 3 or 4
• Patients with ASA classification 5 or higher
• Contraindications against contrast enhanced angiography (a.e. massive hyperthyroidism)
• Patients with increased risk of intraoperative rupture
• Patients with access vessel which are too tortuous, narrow or any kind of reason that would lead to failure of introducing and advancing an introducer sheath

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BGP Stent Graft System; BGP Stent Graft System as bridging stent in Fenestrated Endovascular Repair (FEVAR) for complex aortic aneurysms	Device: BeGraft Peripheral (BGP) Stent Graft System as bridging stent; BGP Stent Graft System as bridging stent; Other Names: implant of stent graft BGP

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy endpoint (1) - Technical success	Successful introduction and deployment of the BeGraft Peripheral (BGP) balloon expandable covered stent Graft System (Bentley Innomed, Hechingen, Germany) implanted as bridging stent in FEVAR	1 day post-op
Efficacy endpoint (2) ) Bridging stent patency at 12 months	defined as absence of restenosis (≥50% stenosis) or sole target vessel occlusion based on CT Angio at 12 months	12 months post-op
Safety endpoint at 12 months	Absence of procedure related complications and bridging stent related endoleaks at 12 months	12 months post-op

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Bridging stent patency post-procedure	Bridging stent patency post-op and at 6-, 12- and 24-months, defined as absence of restenosis (≥50% stenosis) or sole target vessel occlusion based on Duplex ultrasound or CT Angio	1 day post-op, 6-, 12, and 24- months post-op
Freedom from bridging stent related endoleaks post-procedure	Freedom from bridging stent related endoleaks post-op and at 6-, 12- and 24- months, based on imaging (duplex ultrasound, CT angiography)	1 day post-op, 6-, 12, and 24- months post-op
Freedom from bridging stent related secondary intervention post-procedure	Freedom from bridging stent related secondary intervention post-op, 6-, 12- and 24- months	1 day post-op, 6-, 12, and 24- months post-op
Freedom from type I & III endoleaks post-procedure	Freedom from type I & III endoleaks post procedure and at 6, 12 and 24-months, based on imaging (duplex ultrasound, CT angiography)	1 day post-op, 6-, 12, and 24- months post-op
30-day mortality		30 days post-op
Freedom from stent graft migration post-procedure	defined as freedom from stent graft migration (more than 10 mm)	1 day post-op, 6-, 12, and 24- months post-op
Freedom from AAA diameter increase	defined as more than 5mm increase in maximum diameter measured at 6- , 12- and 24- months as compared to postop-implantation, based on imaging (duplex ultrasound or CT Angiography)	6-, 12, and 24- months post-op
Freedom from aneurysm related secondary endovascular procedures post-procedure	Freedom from aneurysm related secondary endovascular procedures	1 day post-op, 6-, 12, and 24- months post-op
Freedom from conversion to open surgical repair post-procedure	Freedom from conversion to open surgical repair post-op	1 day post-op, 6-, 12, and 24- months post-op
Freedom from aneurysm related mortality post-procedure	Freedom from aneurysm related mortality post-procedure	1 day post-op, 6-, 12, and 24- months post-op
Freedom from aneurysm rupture within 12- and 24-months post-implantation	Freedom from aneurysm rupture within 12- and 24-months post-implantation	12, and 24- months post-op
Freedom from any major adverse events post-procedure	Freedom from any major adverse events post-procedure	1 day post-op, 6-, 12, and 24- months post-op
Health Related Quality of Life scores	Health Related Quality of Life scores at 12- and 24-months post implantation	12- and 24-months post-op

Collaborators and Investigators

• Sponsor: Dr. Sabrina Overhagen
• Investigators: Principal Investigator: Eric Verhoeven, Prof. Dr., Foundation for Cardiovascular Research and Education

Study record dates

Study Major Dates

• Study Start (Actual): March 18, 2021
• Primary Completion (Actual): July 19, 2022
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: June 12, 2019
• First Submitted That Met QC Criteria: June 13, 2019
• First Posted (Actual): June 14, 2019

Study Record Updates

• Last Update Posted (Actual): November 8, 2023
• Last Update Submitted That Met QC Criteria: November 7, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Wounds and Injuries; Aortic Diseases; Rupture; Aneurysm; Aortic Aneurysm; Aortic Aneurysm, Abdominal; Aortic Aneurysm, Thoracoabdominal
• Other Study ID Numbers: FCRE-200504

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No